Unveiling the antibody–drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s12032-022-01884-9.pdf
Reference77 articles.
1. Chang-Qing Y, et al. Recent treatment progress of triple negative breast cancer. Prog Biophys Mol Biol. 2020;151:40–53. https://doi.org/10.1016/J.PBIOMOLBIO.2019.11.007.
2. Yin L, Duan J-J, Bian X-W, Yu S-C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020. https://doi.org/10.1186/s13058-020-01296-5.
3. Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–98. https://doi.org/10.1158/2159-8290.CD-18-1177.
4. Wali VB, et al. Identification and validation of a novel biologics target in triple negative breast cancer. Sci Rep. 2019. https://doi.org/10.1038/s41598-019-51453-w.
5. Marei HE, Cenciarelli C, Hasan A. Potential of antibody–drug conjugates (ADCs) for cancer therapy. Cancer Cell Int. 2022. https://doi.org/10.1186/S12935-022-02679-8.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer;Pharmaceutics;2024-04-13
2. Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes;Journal of Chemotherapy;2024-02-13
3. Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers;Clinical Medicine Insights: Oncology;2024-01
4. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer;Technology in Cancer Research & Treatment;2024-01
5. Beyond the Horizon: A Cutting-Edge Review of the Latest Checkpoint Inhibitors in Cancer Treatment;Cancer Investigation;2023-10-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3